[Continuous dopaminergic stimulation in Parkinson disease].
Obeso
J A
JA
Luquin
M R
MR
Vaamonde
J
J
Grandas
F
F
Pastor
M A
MA
Artieda
J
J
Martínez-Lage
J M
JM
D001058:Apomorphine / Q000008:administration & dosage* / Q000627:therapeutic use; D015259:Dopamine Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D004873:Ergolines / Q000008:administration & dosage*; D006801:Humans; D007262:Infusions, Intravenous; D007263:Infusions, Parenteral; D007980:Levodopa / Q000008:administration & dosage* / Q000627:therapeutic use; D008090:Lisuride / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D010078:Oxazines / Q000008:administration & dosage* / Q000627:therapeutic use; D010300:Parkinson Disease / Q000188:drug therapy* / Q000503:physiopathology; D010477:Perfusion / Q000379:methods
D015259:Dopamine Agents; D004873:Ergolines; D010078:Oxazines; C042631:naxagolide; D007980:Levodopa; D008090:Lisuride; D001058:Apomorphine
Estimulación dopaminérgica continua en la enfermedad de Parkinson.